Determination of minimum serum concentration to develop scaffold free micro-tissue

Abstract

Objective. Formation of three-dimensional (3D) micro-tissues without scaffolds are widely used not only to define in vivo tissue formation mechanisms but also the development of different tissue-specific drugs. However, depending on high serum and growth factor concentrations, it would be hard to identify major effective biological cues on micro-tissue formation. The aim of the study is to determine the effect of different serum concentrations on Human Umbilicial Vein Endothelial Cells (HUVECs) micro-tissue formation. Methods. Micro-tissue of HUVEC line was formed by using 3D petri dish technique with medium containing 0%, 1%, 5% and 10% fetal bovine serum (FBS). On the 7^th day after micro-tissue formation, live/dead cells analysis was conducted. Micrograph taken on days 1, 3, 5 and 7^th of micro-tissue formation were determined by image analysis with ImageJ. Results. Sizes of micro-tissue formed with 0% FBS on day 1 and 3 determined as 277 ± 12 µm and 279 ± 20 µm, respectively; however, especially on day 7 micro-tissue size significantly decreased to 229 ± 6 µm. When live/dead analysis results were examined, high cell viability was observed in 5% and 10% FBS concentration. Although micro-tissue like structures were observed in 0% and 1% FBS concentrations dead cell ratio considerably increased compared to 5% and 10% FBS concentration. Conclusions. It has been determined that 0% and 1% serum are appropriate for determining the efficacy of biomimetic peptides and different extracellular matrix proteins on micro-tissue formation parameters of HUVEC. High cell viability in micro-tissues was observed with 5% and 10% serum concentrations.

Keywords

• micro-tissue,three-dimensional cell culture,serum concentration

References

1. [1] Matsusaki M, Case CP, Akashi M. Three-dimensional cell culture technique and pathophysiology. Adv Drug Deliv Rev 2014;74:95-103.
2. [2] Michelini E, Cevenini L, Mezzanotte L, Coppa A, Roda A. Cell-based assays: fuelling drug discovery. Anal Bioanal Chem 2010;398:227-38.
3. [3] Drewe J, Cai SX. Cell-based apoptosis assays in oncology drug discovery. Expert Opin Drug Discov 2010;5:583-96.
4. [4] Vogel V, Baneyx G. The tissue engineering puzzle: a molecular perspective. Annu Rev Biomed Eng 2003;5:441-63.
5. [5] Rosa V, Zhang Z, Grande R, Nör J. Dental pulp tissue engineering in full-length human root canals. J Dent Res 2013;92:970-5.
6. [6] Kelm JM, Fussenegger M. Microscale tissue engineering using gravity-enforced cell assembly. Trends Biotechnol. 2004;22:195-202.
7. [7] Kelm JM, Djonov V, Ittner LM, Fluri D, Born W, Hoerstrup SP, et al. Design of custom-shaped vascularized tissues using microtissue spheroids as minimal building units. Tissue Eng 2006;12:2151-60.
8. [8] Rouwkema J, Rivron NC, van Blitterswijk CA. Vascularization in tissue engineering. Trends Biotechnol 2008;26:434-41.

9. [9] Dissanayaka W, Zhu L, Hargreaves K, Jin L, Zhang C. Scaffold-free prevascularized microtissue spheroids for pulp regeneration. J Dent Res 2014;93:1296-303.
10. [10] Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell 2014;14:141-5.
11. [11] Karnieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy 2017;19:155-69.
12. [12] Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014;345:216-20.
13. [13] Kim CS, Mout R, Zhao Y, Yeh Y-C, Tang R, Jeong Y, et al. Co-delivery of protein and small molecule therapeutics using nanoparticle-stabilized nanocapsules. Bioconjug Chem 2015;26:950-4.
14. [14] Rouwkema J, Khademhosseini A. Vascularization and angiogenesis in tissue engineering: beyond creating static networks. Trends Biotechnol 2016;34:733-45.
15. [15] Karaman O, Onak G, Demirci EA, Kahraman E. Integrin binding peptide promotes in vitro wound closure in the L929 mouse fibroblasts. Eur Res J 2017;3:207-13.
16. [16] Gstraunthaler G, Lindl T, van der Valk J. A plea to reduce or replace fetal bovine serum in cell culture media. Cytotechnology 2013;65:791-3.
17. [17] Napolitano AP, Dean DM, Man AJ, Youssef J, Ho DN, Rago AP, et al. Scaffold-free three-dimensional cell culture utilizing micromolded nonadhesive hydrogels. Biotechniques 2007;43:494-500.
18. [18] Sanz-Nogués C, O’Brien T. In vitro models for assessing therapeutic angiogenesis. Drug Discov Today 2016;21:1495-503.